JP Morgan Chase
KPTI icon

JP Morgan Chase’s Karyopharm Therapeutics KPTI Stock Holding History

JP Morgan Chase’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.5K Sell
471
-1,270
-73% -$9.68K ﹤0.01% 6978
2025
Q4 		$12.8K Buy
1,741
+1,191
+217% +$7.28K ﹤0.01% 6605
2025
Q3 		$3.6K Sell
550
-255,893
-100% -$1.38M ﹤0.01% 6825
2025
Q2 		$1.11M Buy
256,443
+85,653
+50% +$420K ﹤0.01% 4310
2025
Q1 		$639K Buy
170,790
+152,376
+828% +$1.3M ﹤0.01% 4630
2024
Q4 		$187K Sell
18,414
-73,968
-80% -$894K ﹤0.01% 5502
2024
Q3 		$1.15M Buy
92,382
+7,325
+9% +$91K ﹤0.01% 4380
2024
Q2 		$1.11M Sell
85,057
-6,782
-7% -$112K ﹤0.01% 4209
2024
Q1 		$2.08M Buy
91,839
+13,098
+17% +$230K ﹤0.01% 3815
2023
Q4 		$1.02M Buy
78,741
+2,666
+4% +$35.9K ﹤0.01% 4315
2023
Q3 		$1.53M Buy
76,075
+70,113
+1,176% +$1.57M ﹤0.01% 3761
2023
Q2 		$160K Sell
5,962
-6,749
-53% -$291K ﹤0.01% 5209
2023
Q1 		$742K Sell
12,711
-86,100
-87% -$4.25M ﹤0.01% 4244
2022
Q4 		$5.04M Buy
98,811
+86,863
+727% +$6.02M ﹤0.01% 2806
2022
Q3 		$978K Sell
11,948
-330
-3% -$24.6K ﹤0.01% 4027
2022
Q2 		$830K Sell
12,278
-35,631
-74% -$3.27M ﹤0.01% 4231
2022
Q1 		$5.3M Sell
47,909
-1,651
-3% -$206K ﹤0.01% 2960
2021
Q4 		$4.78M Buy
49,560
+18,565
+60% +$1.85M ﹤0.01% 3097
2021
Q3 		$2.71M Sell
30,995
-1,220
-4% -$127K ﹤0.01% 3527
2021
Q2 		$4.99M Buy
32,215
+9,565
+42% +$1.39M ﹤0.01% 3050
2021
Q1 		$3.58M Buy
22,650
+318
+1% +$67K ﹤0.01% 3258
2020
Q4 		$5.19M Buy
22,332
+1,066
+5% +$247K ﹤0.01% 2781
2020
Q3 		$4.65M Buy
21,266
+3,187
+18% +$780K ﹤0.01% 2629
2020
Q2 		$5.14M Buy
18,079
+897
+5% +$265K ﹤0.01% 2434
2020
Q1 		$4.95M Sell
17,182
-6,650
-28% -$1.83M ﹤0.01% 2271
2019
Q4 		$6.85M Buy
23,832
+9,518
+66% +$2.06M ﹤0.01% 2435
2019
Q3 		$2.06M Buy
14,314
+630
+5% +$85.4K ﹤0.01% 3398
2019
Q2 		$1.26M Sell
13,684
-218
-2% -$17.5K ﹤0.01% 3700
2019
Q1 		$1.22M Buy
13,902
+6,070
+78% +$673K ﹤0.01% 3686
2018
Q4 		$1.1M Sell
7,832
-290
-4% -$48.9K ﹤0.01% 3687
2018
Q3 		$2.08M Buy
8,122
+19
+0.2% +$5.25K ﹤0.01% 3443
2018
Q2 		$2.06M Sell
8,103
-11,188
-58% -$2.77M ﹤0.01% 3395
2018
Q1 		$3.88M Sell
19,291
-662
-3% -$132K ﹤0.01% 2785
2017
Q4 		$2.87M Sell
19,953
-527
-3% -$84.6K ﹤0.01% 3093
2017
Q3 		$3.34M Buy
20,480
+18,081
+754% +$2.59M ﹤0.01% 2851
2017
Q2 		$326K Sell
2,399
-32,175
-93% -$4.76M ﹤0.01% 3863
2017
Q1 		$6.66M Buy
34,574
+7,082
+26% +$1.14M ﹤0.01% 2230
2016
Q4 		$3.88M Buy
27,492
+2,559
+10% +$346K ﹤0.01% 2656
2016
Q3 		$3.64M Buy
24,933
+801
+3% +$96.3K ﹤0.01% 2446
2016
Q2 		$2.43M Buy
24,132
+5,452
+29% +$708K ﹤0.01% 2704
2016
Q1 		$2.5M Buy
18,680
+4,198
+29% +$463K ﹤0.01% 2586
2015
Q4 		$2.88M Buy
14,482
+9,119
+170% +$1.97M ﹤0.01% 2563
2015
Q3 		$846K Sell
5,363
-242
-4% -$64.7K ﹤0.01% 3200
2015
Q2 		$2.29M Buy
5,605
+2,438
+77% +$1.05M ﹤0.01% 2834
2015
Q1 		$1.45M Sell
3,167
-153
-5% -$66K ﹤0.01% 3028
2014
Q4 		$1.86M Sell
3,320
-317
-9% -$180K ﹤0.01% 3011
2014
Q3 		$1.91M Buy
3,637
+82
+2% +$46.3K ﹤0.01% 2955
2014
Q2 		$2.48M Sell
3,555
-1,208
-25% -$562K ﹤0.01% 2416
2014
Q1 		$2.21M Sell
4,763
-2,476
-34% -$1.26M ﹤0.01% 2510
2013
Q4 		$2.49M Buy
+7,239
New +$2M ﹤0.01% 2622

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

JP Morgan Chase's KPTI Position: Q1 2026 in Review

JP Morgan Chase reduced its Karyopharm Therapeutics (KPTI) stake by 73% in Q1 2026, selling an estimated $9.68K and leaving 471 shares worth $2.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6978.

JP Morgan Chase first reported a position in KPTI in Q4 2013 and has held it in 50 quarters since. The position peaked at $6.85M in Q4 2019. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • JP Morgan Chase held 471 shares of Karyopharm Therapeutics worth $2.5K as of Q1 2026.
  • JP Morgan Chase sold 1,270 Karyopharm Therapeutics shares in Q1 2026, an estimated $9.68K.
  • Karyopharm Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6978 holding.
  • JP Morgan Chase first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 50 quarters since.
  • JP Morgan Chase's Karyopharm Therapeutics position peaked at $6.85M in Q4 2019.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.